In addition, Parameswaran et al. recently verified that human T-cell lymphoma cell lines express CD6 at high levels and found that a CD6-targeted antibody–drug combination (termed anti-CD6-ADC) reverses the growth of tumors in vivo and specifically kills T-cell lymphoma cells in vitro, suggesting that CD6 could be a good marker for the treatment of these very aggressive T-cell lymphomas [93]. This evidence concerns the gene CD6 and T-cell non-Hodgkin lymphoma.